Mou Ruiyu, Jin Xinyao, Li Wenjie, Wu Mingxin, Liu Xiaodi, Liu Zhao, Guo Shanqi, Li Xiaojiang, Jia Yingjie
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome.
Medicine (Baltimore). 2020 Oct 23;99(43):e22591. doi: 10.1097/MD.0000000000022591.
COVID-19 is now a global pandemic. Although there are very few studies describing the characteristics of SARS-CoV-2 infections in patients with prostate cancer, these patients are likely to be more susceptible to COVID-19 than healthy people because of their immunosuppressed state. However, there is no evidence that prostate cancer is a risk factor for COVID-19.
We searched the Wanfang database, the China Science Journal Citation Report (VIP database), the China National Knowledge Infrastructure (CNKI), Web of Science, EMBASE, PubMed, and the Cochrane Library for studies related to the topic. We designed a standardized data extraction sheet and used Epidata software 3.1 for data extraction. In accordance with the Cochrane 5.1.0 standard, both a quality assessment and a risk assessment were carried out for the research meeting the inclusion criteria. The data were analyzed using Revman 5.3 and Stata 13.0 software.
The study integrated existing research findings and a meta-analysis of the data to investigate the prevalence of prostate cancer in males infected with SARS-CoV-2 and the adverse clinical outcomes in male patients with or without COVID-19.
The results of this research may provide a basis for judging if prostate cancer is a risk factor for males infected with SARS-CoV-2, and the findings can effectively help to prevent COVID-19 in patients with prostate cancer.
Ethics approval is not required for this systematic review as it will involve the collection and analysis of secondary data. The results of the review will be reported in international peer-reviewed journals PRORPERO REGISTRATION NUMBER:: CRD42020194071.
新型冠状病毒肺炎（COVID-19）现已成为全球大流行疾病。尽管描述前列腺癌患者感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特征的研究非常少，但由于这些患者处于免疫抑制状态，他们可能比健康人更容易感染COVID-19。然而，尚无证据表明前列腺癌是COVID-19的危险因素。
我们检索了万方数据库、《中文科技期刊数据库》（维普数据库）、中国知网、科学网、EMBASE、PubMed和Cochrane图书馆，查找与该主题相关的研究。我们设计了标准化的数据提取表，并使用Epidata软件3.1进行数据提取。根据Cochrane 5.1.0标准，对符合纳入标准的研究进行质量评估和风险评估。使用Revman 5.3和Stata 13.0软件对数据进行分析。
该研究整合了现有研究结果并对数据进行荟萃分析，以调查感染SARS-CoV-2的男性中前列腺癌的患病率以及有或无COVID-19的男性患者的不良临床结局。
本研究结果可为判断前列腺癌是否为感染SARS-CoV-2男性的危险因素提供依据，其结果可有效帮助预防前列腺癌患者感染COVID-19。
本系统评价无需伦理批准，因为它将涉及二手数据的收集和分析。该评价结果将在国际同行评审期刊上发表。系统评价注册编号：CRD42020194071。
